BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.45
+0.00 (+0.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.45
Open0.44
Bid0.37 x 500
Ask0.70 x 9500
Day's Range0.44 - 0.48
52 Week Range0.25 - 1.50
Volume238,613
Avg. Volume467,466
Market Cap45.03M
Beta2.44
PE Ratio (TTM)-6.82
EPS (TTM)-0.07
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • Is It Time To Buy Bio-Path Holdings Inc (BPTH)?
    Simply Wall St.9 days ago

    Is It Time To Buy Bio-Path Holdings Inc (BPTH)?

    Bio-Path Holdings Inc (NASDAQ:BPTH), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in the over the last fewRead More...

  • GlobeNewswire2 months ago

    Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference

    HOUSTON, Sept. 05, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic ...

  • Associated Press2 months ago

    Bio-Path reports 2Q loss

    The Bellaire, Texas-based company said it had a loss of 3 cents per share. The company's shares closed at 35 cents. A year ago, they were trading at $1.73. _____ This story was generated by Automated Insights ...

  • GlobeNewswire2 months ago

    Bio-Path Holdings Reports Second Quarter 2017 Financial Results

    HOUSTON, Aug. 10, 2017-- Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...

  • GlobeNewswire3 months ago

    Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017

    HOUSTON, Aug. 03, 2017-- Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...

  • Associated Press5 months ago

    Bio-Path reports 1Q loss

    The Bellaire, Texas-based company said it had a loss of 1 cent per share. The company's shares closed at 59 cents. A year ago, they were trading at $2.75. _____ This story was generated by Automated Insights ...

  • Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher
    Zacks6 months ago

    Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher

    Bio-Path Holdings, Inc. (BPTH) shares rose over 13% in the last trading session.

  • Associated Press7 months ago

    Bio-Path reports 4Q loss

    The Bellaire, Texas-based company said it had a loss of 1 cent per share. The biotechnology company posted revenue of $13,000 in the period. For the year, the company reported that its loss widened to ...

  • How Noodles & Co (NDLS) Stacks Up Against Its Peers
    Insider Monkey10 months ago

    How Noodles & Co (NDLS) Stacks Up Against Its Peers

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]